Cagrillintide/GLP-S 5/5mg

Product Overview

The Cagrilintide / GLP-S (Research Grade Semaglutide) blend is a research peptide formulation that combines a long-acting amylin analog (cagrilintide) and a glucagon-like peptide-1 (GLP-1) receptor agonist (semaglutide). This dual approach harnesses two complementary hormonal pathways for advanced study in metabolic regulation and weight management. The product is intended strictly for laboratory research use, not for human or veterinary applications.

Key Features

• • • Blend Components: Long-acting amylin analogue (Cagrilintide) and GLP-1 receptor agonist (Research Grade Semaglutide)

    • Peptide Structure: Cagrilintide consists of a modified amylin sequence with enhanced half-life through lipidation and amino acid substitutions; semaglutide is a 31-amino acid GLP-1 analog with modifications for improved stability and bioavailability

    • Molecular Formula: Cagrilintide: C256H377N65O78; Semaglutide: C187H291N45O59

    • Molecular Weight: Cagrilintide: ~5100 Da; Semaglutide: 4113.64 Da

    • CAS Numbers: Cagrilintide: 1354632-24-2; Semaglutide: 910463-68-2

Intended Research Applications

• • • Investigation of dual hormone synergy in appetite and weight regulation

    • Studies on glucose metabolism, insulin secretion, and glycemic control

    • Preclinical evaluation in models of obesity, type 2 diabetes, and metabolic disease

    • Exploration of pharmacokinetics and receptor signaling pathways

Product Attributes

Compliance Disclaimer

For Research Use Only: This product is not intended for human or veterinary use. Supply is limited strictly to laboratory research, analytical assay development, or investigative procedures only.

Not for Human Consumption: Any clinical or diagnostic use, or use as a drug, food, or cosmetic is strictly prohibited.

Handling Precautions: Employ appropriate personal protective equipment and follow institutional safety protocols for peptide handling and disposal.

Additional Information

This Cagrilintide / GLP-S (Research Grade Semaglutide) blend should be reconstituted with 0.9% benzyl alcohol solution (Bacteriostatic Water) in accordance with your laboratory’s protocols.

No therapeutic or diagnostic claims are made for this compound. All statements relate exclusively to laboratory research findings.